Publications by authors named "Linda de Bruin"
Background: The presence of T cells and suppressive myeloid cells in epithelial ovarian cancer (EOC) correlate with good and bad clinical outcome, respectively. This suggests that EOC may be sensitive to adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TIL), provided that immunosuppression by myeloid-derived suppressor cells and M2 macrophages is reduced. Platinum-based chemotherapy can alleviate such immunosuppression, potentially creating a window of opportunity for T cell-based immunotherapy.
View Article and Find Full Text PDFPurpose: The availability of (neo)antigens and the infiltration of tumors by (neo)antigen-specific T cells are crucial factors in cancer immunotherapy. In this study, we aimed to investigate the targetability of (neo)antigens in advanced progessive melanoma and explore the potential for continued T-cell-based immunotherapy.
Experimental Design: We examined a cohort of eight patients with melanoma who had sequential metastases resected at early and later time points.
Article Synopsis
- Human colorectal cancer-derived cancer-associated fibroblasts (CAFs) can cross-present neoantigens, which enhances their ability to interact with tumor-specific CD8+ T cells compared to normal fibroblasts.
- The study utilized advanced genetic techniques and assays to identify the molecular mechanisms involved, particularly highlighting the role of the lysosomal protease cathepsin S.
- Results showed that interaction between CAFs and CD8+ T cells can lead to reduced T cell activation and increased exhaustion, suggesting that CAFs may negatively impact tumor immunity.
Introduction: Treatment with anti-PD-1 immunotherapy does not lead to long-lasting clinical responses in approximately 60% of patients with metastatic melanoma. These refractory patients, however, can still respond to treatment with tumour infiltrating lymphocytes (TIL) and interferon-alpha (IFNa). A combination of TIL, pegylated-interferon-alpha (PEG-IFNa) and anti-PD-1 is expected to provide a safe, feasible and effective therapy for patients with metastatic melanoma, who are refractory to standard of care treatment options.
View Article and Find Full Text PDFBackground: Adoptive cell therapy (ACT) with tumor-reactive T cells has shown consistent clinical efficacy. We evaluated the response to ACT in combination with interferon alpha (IFNa) preconditioning in patients with stage IV metastatic melanoma, most of which were progressive on cytotoxic T-lymphocyte-associated protein 4 and/or programmed cell death protein 1 checkpoint blockade therapy.
Methods: Thirty-four patients were treated with ex vivo expanded tumor reactive T cells, derived from mixed lymphocyte autologous tumor cultures, or with autologous tumor-infiltrating lymphocytes and evaluated for clinical response.
Nonoperative treatment for lumbar spinal stenosis with neurogenic claudication.
Cochrane Database Syst Rev
August 2013
Background: Lumbar spinal stenosis with neurogenic claudication is one of the most commonly diagnosed and treated pathological spinal conditions. It frequently afflicts the elderly population.
Objectives: To systematically review the evidence for the effectiveness of nonoperative treatment of lumbar spinal stenosis with neurogenic claudication.
Study Design: Systematic review.
Objective: To systematically review the evidence for the effectiveness of nonoperative treatment of lumbar spinal stenosis with neurogenic claudication.
Summary Of Background Data: Neurogenic claudication can significantly impact functional ability, quality of life, and independence in the elderly.